MX2023005520A - Combinaciones de inhibidores de cinasa para tratamiento de cancer. - Google Patents

Combinaciones de inhibidores de cinasa para tratamiento de cancer.

Info

Publication number
MX2023005520A
MX2023005520A MX2023005520A MX2023005520A MX2023005520A MX 2023005520 A MX2023005520 A MX 2023005520A MX 2023005520 A MX2023005520 A MX 2023005520A MX 2023005520 A MX2023005520 A MX 2023005520A MX 2023005520 A MX2023005520 A MX 2023005520A
Authority
MX
Mexico
Prior art keywords
combinations
inhibitor
kinase inhibitor
cancer treatment
inhibitor combinations
Prior art date
Application number
MX2023005520A
Other languages
English (en)
Inventor
Erik Wilker
Andreas Machl
Remigiusz Kaleta
Anderson Clark
Bayard Huck
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2023005520A publication Critical patent/MX2023005520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a combinaciones de amida de ácido 4-[(S)-2-azetidin-1-il-1-(4-cloro-3-trifluorometil-fenil)-etilami no]-quinazolin-8-carboxílico y/o sus sales y solvatos fisiológicamente aceptables, y un inhibidor de MEK cinasa, y como un tercer inhibidor opcional, con un inhibidor de EGFR, y al uso de estas combinaciones para el tratamiento de cáncer, y a combinaciones de amida de ácido 4-[(S)-2-azetidin-1-il-1-(4-cloro- 3-trifluorometil-fenil)-etilamino]-quinazolin-8-carboxílico y/o sus sales y solvatos fisiológicamente aceptables, y un inhibidor de EGFR.
MX2023005520A 2020-11-16 2021-11-15 Combinaciones de inhibidores de cinasa para tratamiento de cancer. MX2023005520A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063114144P 2020-11-16 2020-11-16
US202163162649P 2021-03-18 2021-03-18
PCT/EP2021/081612 WO2022101459A1 (en) 2020-11-16 2021-11-15 Kinase inhibitor combinations for cancer treatment

Publications (1)

Publication Number Publication Date
MX2023005520A true MX2023005520A (es) 2023-05-23

Family

ID=78819455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005520A MX2023005520A (es) 2020-11-16 2021-11-15 Combinaciones de inhibidores de cinasa para tratamiento de cancer.

Country Status (9)

Country Link
US (1) US20240024324A1 (es)
EP (1) EP4243819A1 (es)
JP (1) JP2023551408A (es)
KR (1) KR20230110296A (es)
AU (1) AU2021376892A1 (es)
CA (1) CA3201799A1 (es)
IL (1) IL302951A (es)
MX (1) MX2023005520A (es)
WO (1) WO2022101459A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
MXPA06003557A (es) 2003-09-30 2006-06-20 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
AU2004283751B2 (en) 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
EP1687305B1 (en) 2003-11-21 2008-07-09 Novartis AG 1h-imidazoquinoline derivatives as protein kinase inhibitors
BRPI0417498A (pt) 2003-12-09 2007-05-29 Us Gov Health & Human Serv método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
JP5214971B2 (ja) 2004-10-20 2013-06-19 メルク セローノ ソシエテ アノニム ３−アリルアミノピペリジン誘導体
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010093419A1 (en) 2009-02-11 2010-08-19 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
PE20140966A1 (es) 2010-11-24 2014-08-06 Merck Patent Gmbh Quinazolincarboxamida azetidinas
NZ725361A (en) * 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
KR20170090498A (ko) * 2014-12-11 2017-08-07 메르크 파텐트 게엠베하 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 퀴나졸린 유도체의 조합

Also Published As

Publication number Publication date
IL302951A (en) 2023-07-01
KR20230110296A (ko) 2023-07-21
US20240024324A1 (en) 2024-01-25
EP4243819A1 (en) 2023-09-20
CA3201799A1 (en) 2022-05-19
JP2023551408A (ja) 2023-12-08
WO2022101459A1 (en) 2022-05-19
AU2021376892A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
CR20220070A (es) Inhibidores de parp1
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CY1117546T1 (el) Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου
MX2023008420A (es) Combinación de un inhibidor de dominios asociados mejorados transcripcionales (tead) de 3-(imidazol-4-il)-4-(amino)- bencenosulfonamida con un inhibidor del factor de crecimiento epidérmico (egfr) y/o un inhibidor de proteína cinasa-cinasas activadas por mitógen (mek) para usarse en el tratamiento de cáncer de pulmón.
MX2022012178A (es) Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso.
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
ZA202207804B (en) Compounds and uses thereof
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
MX2022006402A (es) Uso de bi853520 en tratamiento contra el cancer.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2022009308A (es) Compuestos y usos de estos.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
MX2022009367A (es) Compuestos y usos de estos.
MX2021003732A (es) Inhibidores de menina de molécula pequeña.
CO2022000266A2 (es) Inhibidores de enzimas
MX2023005436A (es) Compuestos y usos de estos.